Advances in the management of hyperlipidemia-induced atherosclerosis

References

• Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. J. Lipid Res.45(9), 1583–1593 (2004).
   PubMed Web of Science ®Google Scholar
• Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J. Lipid Res.46(2), 179–190 (2005).
   PubMed Web of Science ®Google Scholar
• Steinberg D. Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J. Lipid Res.46(10), 2037–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J. Lipid Res.47(7), 1339–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Steinberg D. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it – almost. J. Lipid Res.47(1), 1–14 (2006).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc. Natl Acad. Sci. USA70(10), 2804–2808 (1973).
   PubMed Web of Science ®Google Scholar
• Villeger L, Abifadel M, Allard D et al. The UMD-LDLR database: additions to the software and 490 new entries to the database. Hum. Mut.20(2), 81–87 (2002).
   PubMed Web of Science ®Google Scholar
• Innerarity TL, Weisgraber KH, Arnold KS et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc. Natl Acad. Sci. USA84(19), 6919–6923 (1987).
   PubMed Web of Science ®Google Scholar
• Miserez AR, Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.15(10), 1719–1729 (1995).
   PubMed Web of Science ®Google Scholar
• Genest JJ, Jr., Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation85(6), 2025–2033 (1992).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest.52(7), 1544–1568 (1973).
   PubMed Web of Science ®Google Scholar
• Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of Type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metab.89(6), 2601–2607 (2004).
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta- analysis of population-based prospective studies. J. Cardiovasc. Risk3(2), 213–219 (1996).
   PubMedGoogle Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110(2), 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin. Ther.29(5), 778–794 (2007).
   PubMed Web of Science ®Google Scholar
• Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA256(20), 2835–2838 (1986).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med.356(13), 1304–1316 (2007).
   PubMed Web of Science ®Google Scholar
• Tall AR. CETP inhibitors to increase HDL cholesterol levels. N. Engl. J. Med.356(13), 1364–1366 (2007).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol.92(2), 152–160 (2003).
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294(19), 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA288(23), 2998–3007 (2002).
   PubMed Web of Science ®Google Scholar
• Illingworth DR. Management of hypercholesterolemia. The Medical clinics of North America,84(1), 23–42 (2000).
   PubMed Web of Science ®Google Scholar
• O’Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J. Am. Coll. Cardiol.43(11), 2142–2146 (2004).
   PubMed Web of Science ®Google Scholar
• Kashani A, Phillips CO, Foody JM et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation114(25), 2788–2797 (2006).
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol.97(8A), 89C–94C (2006).
   PubMed Web of Science ®Google Scholar
• Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am. J. Cardiol.97(8A), 77C–81C (2006).
   PubMed Web of Science ®Google Scholar
• Gibson K, Rindone JP. Experience with statin use in patients with chronic hepatitis C infection. Am. J. Cardiol.96(9), 1278–1279 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology46(5), 1453–1463 (2007).
   PubMed Web of Science ®Google Scholar
• Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment. Pharmacol. Ther.23(11), 1643–1647 (2006).
   PubMed Web of Science ®Google Scholar
• Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis174(1), 193–196 (2004).
   PubMed Web of Science ®Google Scholar
• Bays H. Statin safety: an overview and assessment of the data – 2005. Am. J. Cardiol.97(8A), 6C–26C (2006).
   PubMed Web of Science ®Google Scholar
• Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J. Am. Coll. Cardiol.49(23), 2231–2237 (2007).
   PubMed Web of Science ®Google Scholar
• Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol.40(3), 567–572 (2002).
   PubMed Web of Science ®Google Scholar
• Kasiske BL, Wanner C, O’Neill WC. An assessment of statin safety by nephrologists. Am. J. Cardiol.97(8A), 82C–85C (2006).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Kastelein JJ, Bittner V et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin. J. Am. Soc. Nephrol.2(6), 1131–1139 (2007).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc.80(5), 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol.90(10), 1092–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am. J. Cardiol.99(6A), 47C–55C (2007).
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. JAMA252(18), 2545–2548 (1984).
   PubMedGoogle Scholar
• Parsons WB, Jr. Studies of nicotinic acid use in hypercholesteremia. Changes in hepatic function, carbohydrate tolerance, and uric acid metabolism. Arch. Intern. Med.107, 653–667 (1961).
   PubMedGoogle Scholar
• Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism47(9), 1097–1104 (1998).
   PubMed Web of Science ®Google Scholar
• Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism34(7), 642–650 (1985).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Packard CJ, Patsch JR, Gotto AM, Jr., Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J. Clin. Invest.63(5), 858–867 (1979).
   PubMed Web of Science ®Google Scholar
• Wahlberg G, Walldius G, Olsson AG, Kirstein P. Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia. J. Int. Med.228(2), 151–157 (1990).
   PubMed Web of Science ®Google Scholar
• Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann. Intern. Med.139(12), 996–1002 (2003).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Clofibrate and niacin in coronary heart disease. JAMA231(4), 360–381 (1975).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol.8(6), 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med.345(22), 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med.323(19), 1289–1298 (1990).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation110(23), 3512–3517 (2004).
   PubMed Web of Science ®Google Scholar
• Soga T, Kamohara M, Takasaki J et al. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun.303(1), 364–369 (2003).
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med.9(3), 352–355 (2003).
   PubMed Web of Science ®Google Scholar
• Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem.278(11), 9869–9874 (2003).
   PubMed Web of Science ®Google Scholar
• Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann. Intern. Med.121(4), 252–258 (1994).
   PubMed Web of Science ®Google Scholar
• Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl Acad. Sci. USA103(17), 6682–6687 (2006).
   PubMed Web of Science ®Google Scholar
• Guyton JR, Bays HE. Safety considerations with niacin therapy. Am. J. Cardiol.99(6A), 22C–31C (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg A, Alagona P, Jr., Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am. J. Cardiol.85(9), 1100–1105 (2000).
   PubMed Web of Science ®Google Scholar
• Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O’Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am. J. Cardiol.82(6), 737–743 (1998).
   PubMed Web of Science ®Google Scholar
• Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA284(10), 1263–1270 (2000).
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Guyton JR, Morgan JM et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am. J. Cardiol.82(12A), 74U–81U; discussion 85U–86U (1998).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol–niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA257(23), 3233–3240 (1987).
   PubMed Web of Science ®Google Scholar
• Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Medica Scandinavica223(5), 405–418 (1988).
   PubMed Web of Science ®Google Scholar
• Duval C, Muller M, Kersten S. PPARa and dyslipidemia. Biochim. Biophys. Acta1771(8), 961–971 (2007).
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol.45(2), 185–197 (2005).
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med.317(20), 1237–1245 (1987).
   PubMed Web of Science ®Google Scholar
• Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation85(1), 37–45 (1992).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med.341(6), 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br. Heart J.40(10), 1069–1118 (1978).
   PubMedGoogle Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation102(1), 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366(9500), 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Buse JB. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods. Am. J. Cardiol.99(12 Suppl. 1), S21–S33 (2007).
   PubMedGoogle Scholar
• Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am. J. Cardiol.99(6A), 3C–18C (2007).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol.95(1), 120–122 (2005).
   PubMed Web of Science ®Google Scholar
• Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron92(3), 536–541 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol.98 (4A), 27i–33i (2006).
   PubMed Web of Science ®Google Scholar
• Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med.112(4), 298–304 (2002).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am. J. Cardiol.98(4A), 39i–49i (2006).
   PubMed Web of Science ®Google Scholar
• Marchioli R, Barzi F, Bomba E et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation105(16), 1897–1903 (2002).
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet369(9567), 1090–1098 (2007).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care,28(7), 1547–1554 (2005).
   PubMed Web of Science ®Google Scholar
• Collins AR, Meehan WP, Kintscher U et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol.21(3), 365–371. (2001).
   PubMed Web of Science ®Google Scholar
• Levi Z, Shaish A, Yacov N et al. Rosiglitazone (PPARg-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes. Metab.5(1), 45–50 (2003).
   PubMed Web of Science ®Google Scholar
• Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor g ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest.106(4), 523–531. (2000).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med.356(24), 2457–2471 (2007).
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis. JAMA298(10), 1189–1195 (2007).
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N. Engl. J. Med.357(1), 28–38 (2007).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet366(9493), 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA298(10), 1180–1188 (2007).
   PubMed Web of Science ®Google Scholar
• Delanghe JR, Langlois MR, De Bacquer D et al. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis160(2), 471–476 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson BD, Kip KE, Marroquin OC et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation109(6), 726–732 (2004).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med.336(14), 973–979 (1997).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med.347(20), 1557–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Donnelly R, Manning G. Angiotensin-converting enzyme inhibitors and coronary heart disease prevention. J. Renin Angiotensin Aldosterone Syst.8(1), 13–22 (2007).
   PubMed Web of Science ®Google Scholar
• Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation110, 3849–3857 (2004).
   PubMed Web of Science ®Google Scholar
• Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G. Inhibition of Diet-Induced Atherosclerosis and Endothelial Dysfunction in Apolipoprotein E/Angiotensin II Type 1A Receptor Double-Knockout Mice. Circulation 01.CIR.0000137970.0000147771.AF (2004).
   Google Scholar
• Manson JE, Hsia J, Johnson KC et al. Estrogen plus Progestin and the Risk of Coronary Heart Disease. 523–534 (2003).
   Google Scholar
• Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA284(3), 311–318 (2000).
   PubMed Web of Science ®Google Scholar
• Stamler J, Stamler R, Neaton JD et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA282(21), 2012–2018 (1999).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med.335(14), 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med.339(19), 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333(20), 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA279(20), 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361(9364), 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA285(13), 1711–1718 (2001).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA292(11), 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar